The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Masashi Kondo
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly O.; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Novartis; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly O.; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hye Ryun Kim
Speakers' Bureau - Ono Pharmaceutical; Roche/Genentech
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Ji-Youn Han
Stock and Other Ownership Interests - Yuhan
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - ABION; Bristol-Myers Squibb; J Ints Bio; Janssen; Lantern Pharma; Merck; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Maximilian J. Hochmair
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Roche; Takeda
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
Research Funding - Merck
 
Angelo Delmonte
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Kentarou Kudou
Employment - Takeda
 
Takayuki Asato
Employment - Takeda
 
Yuyin Liu
Employment - Takeda
 
Florin Vranceanu
Employment - Takeda
 
Robert J. Fram
Employment - Takeda
Stock and Other Ownership Interests - Baxter; Bristol-Myers Squibb; GE Healthcare; Gilead Sciences; Johnson & Johnson; Medtronic; Pfizer; Takeda; Teva; Viatris; Zimmer Biomet; Zimvie
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Turning Point Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; EQRx; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Roche; Sanofi; Seagen; Takeda; Turning Point Therapeutics
Research Funding - Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics; MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell; Turning Point Therapeutics (Inst)
Expert Testimony - Merck KGaA; Roche